10-QPeriod: Q2 FY2019

IDEXX LABORATORIES INC /DE Quarterly Report for Q2 Ended Jun 30, 2019

Filed August 1, 2019For Securities:IDXX

Summary

IDEXX Laboratories, Inc. reported solid financial results for the second quarter of 2019, demonstrating continued revenue growth driven primarily by its Companion Animal Group (CAG) segment. Total revenue increased by 6.8% year-over-year to $620.1 million, with organic revenue growth of 8.7%. Net income attributable to stockholders rose to $125.7 million, a significant increase from $108.7 million in the prior year period, translating to diluted earnings per share of $1.43 compared to $1.23. The company continues to see strong performance in recurring revenue within its CAG segment, particularly from consumables and reference laboratory services, supported by an expanding instrument installed base. While the LPD segment experienced a slight revenue decrease due to market factors like African Swine Fever and reduced bovine testing, the overall financial health remains robust, bolstered by effective cost management and operational efficiencies. The company also highlighted its liquidity position and reaffirmed its financial guidance, indicating confidence in its ongoing strategy and ability to generate shareholder value.

Financial Highlights

52 data points
Beta

Revenue

$620.10M

57.7% Gross Margin

Net Income

$125.70M

20.3% Net Margin

EPS (Diluted)

$1.43

Total Assets

$1.72B

Cash & Equivalents

$110.84M

Free Cash Flow

$103.32M

Financial Statements
Beta
Revenue$620.10M
Cost of Revenue$262.25M
Gross Profit$357.85M
R&D Expenses$32.26M
Operating Income$164.28M
Interest Expense$8.19M
Net Income$125.70M
EPS (Basic)$1.46
EPS (Diluted)$1.43
Shares Outstanding (Basic)86.22M
Shares Outstanding (Diluted)87.61M

Key Highlights

  • 1Total revenue for the quarter increased by 6.8% to $620.1 million, with organic revenue growth of 8.7%, indicating strong underlying business performance.
  • 2Net income attributable to IDEXX stockholders grew by 15.6% to $125.7 million, with diluted EPS rising to $1.43 from $1.23 year-over-year.
  • 3The Companion Animal Group (CAG) segment remains the primary growth driver, with revenue up 7.9% and organic revenue growth of 9.5%, fueled by strong demand for diagnostics, consumables, and services.
  • 4CAG Diagnostics recurring revenue showed robust growth of 9.1%, driven by IDEXX VetLab consumables and reference laboratory services, reflecting continued market penetration and customer adoption.
  • 5Operating income increased by 12.8% to $164.3 million, demonstrating effective cost management and operational leverage.
  • 6The company maintained a strong liquidity position with $110.8 million in cash and cash equivalents and significant availability under its revolving credit facility.
  • 7Despite some segment-specific headwinds (e.g., LPD segment revenue down 5.4%), the overall diversified business model and strong CAG performance led to positive consolidated results.

Frequently Asked Questions

The primary driver of IDEXX's revenue growth was the strong performance of its Companion Animal Group (CAG) segment. This segment saw a 7.9% increase in revenue, with organic growth of 9.5%, largely attributed to increased volumes in CAG Diagnostics recurring revenue, including IDEXX VetLab consumables and reference laboratory diagnostic services.

Profitability improved significantly. Net income attributable to IDEXX Laboratories, Inc. stockholders increased by 15.6% to $125.7 million, and diluted earnings per share rose to $1.43 from $1.23 in the comparable prior-year period. This was supported by a 7.6% increase in gross profit and a 12.8% increase in operating income.

Yes, the Livestock, Poultry and Dairy (LPD) segment experienced a revenue decrease of 5.4%. This was primarily due to the unfavorable impact of foreign currency movements, a decline in diagnostic testing related to African swine fever outbreaks in China, and lower bovine testing volumes in key regions.

IDEXX maintained a strong liquidity position, with $110.8 million in cash and cash equivalents at June 30, 2019. Net cash provided by operating activities for the six months ended June 30, 2019, was $171.5 million, an increase from the prior year. The company also has substantial borrowing availability under its credit facility, indicating sufficient resources to fund operations and growth.